Sign In
Buy VIVO
$3.90
+0.170 (+4.56%)
At Close: Aug 04, 2026
Meridian Bioscience (VIVO) is on the Move, Here's Why the Trend Could be Sustainable
10:33am, Thursday, 05'th May 2022
Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed th
Why Earnings Season Could Be Great for Meridian Bioscience (VIVO)
10:32am, Thursday, 05'th May 2022
Meridian Bioscience (VIVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Nephros Inc. (NEPH) Reports Q1 Loss, Misses Revenue Estimates
12:05am, Thursday, 05'th May 2022 Zacks Investment Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of -53.85% and 25.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
What Awaits Meridian Bioscience (VIVO) This Earnings Season?
02:47pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.
What Awaits Meridian Bioscience (VIVO) This Earnings Season?
12:02pm, Tuesday, 03'rd May 2022
Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.
Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?
10:37am, Tuesday, 03'rd May 2022 Zacks Investment Research
Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
AMN Healthcare (AMN) to Report Q1 Earnings: What's in Store?
10:35am, Tuesday, 03'rd May 2022 Zacks Investment Research
AMN Healthcare's (AMN) first-quarter results are likely to reflect solid demand in some of the areas of its business.
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
02:01pm, Monday, 02'nd May 2022 Zacks Investment Research
Supply shortage along with pandemic-led incremental mortality rate is likely to have weighed on DaVita's (DVA) first-quarter top line.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
12:25pm, Monday, 02'nd May 2022 Zacks Investment Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
12:21pm, Monday, 02'nd May 2022 Zacks Investment Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
Meridian Bioscience (VIVO) Expected to Beat Earnings Estimates: Should You Buy?
07:00pm, Friday, 29'th Apr 2022 Zacks Investment Research
Meridian Bioscience (VIVO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience (VIVO) Expected to Beat Earnings Estimates: Should You Buy?
04:33pm, Friday, 29'th Apr 2022
Meridian Bioscience (VIVO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Meridian Bioscience (VIVO) Keep the Earnings Surprise Streak Alive?
04:10pm, Friday, 29'th Apr 2022 Zacks Investment Research
Meridian Bioscience (VIVO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Meridian Bioscience (VIVO) Keep the Earnings Surprise Streak Alive?
01:33pm, Friday, 29'th Apr 2022
Meridian Bioscience (VIVO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
03:49pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q2 sales.
